In the Claims

Applicant has submitted a new complete claim set indicating marked up claims with insertions and deletions indicated by underlining and strikeouts, respectively.

1. (Original) A compound of formula (I)

$$R_1$$
 R_2
 R_3
 R_4
 R_5
 R_5
 R_5

or a salt thereof, or a solvate thereof, wherein;

 R_1 and R_2 each independently represents $C_{1\text{--}6}$ alkoxy or halo;

 R_3 and R_4 each independently represents hydrogen, $C_{1\text{-}6}$ alkoxy, aryl $C_{1\text{-}6}$ alkoxy, hydroxy, carboxy $C_{1\text{-}6}$ alkoxy, hydroxy $C_{1\text{-}6}$ alkoxy, dihydroxy $C_{1\text{-}6}$ alkoxy, mono-and di- $(C_{1\text{-}6}$ alkoxy or amino $C_{1\text{-}6}$ alkoxy and;

 $R_{5} \ represents-NR_{s}R_{t} \ wherein \ R_{s} \ and \ R_{t} \ each \ independently \ represent \ hydrogen,$ unsubstituted or substituted $C_{1\text{-}6}$ alkyl, or unsubstituted or substituted heterocyclyl.

- 2. (Original) A compound according to claim 1 wherein R_1 and R_2 each independently represents methoxy or chloro.
- 3. (Previously presented) A compound according to claim 1 wherein R_1 is 5-chloro and R_2 is 6-chloro.
- 4. (Original) A compound according to claim 1 wherein R₃ is hydroxy, methoxy, ethoxy, propoxy, benzyloxy, carboxyethoxy, hydroxyethoxy, dihydoxypropoxy, dimethylaminoethoxy or aminopropoxy.

- 5. (Original) A compound according to claim 1 wherein R₄ is hydrogen or methoxy.
- 6. (Original) A compound according to claim 1 wherein R_s or R_t represent unsubstituted or substituted C_{1-6} alkyl, or unsubstituted or substituted heterocyclyl.
- 7. (Previously presented) A compound according to claim 1 wherein R_s or R_t represent 3-[4-(3-methoxyphenyl)piperazin-1-yl]propyl or 3-[4-(2-pyrimidinyl) piperazin-1-yl]propyl.
- 8. (Original) A compound according to claim 1 wherein R_s or R_t represent an unsubstituted or substituted piperidinyl group.
- 9. (Previously presented) A compound according to claim 1 wherein R_s or R_t represent a 1,2,2,6,6-pentamethylpiperidin-4-yl group or a 2,2,6,6-tetramethylpiperidin-4-yl group.
- 10. (Original) A compound according to claim wherein R_t is hydrogen.
- 11. (Previously presented) A compound according to claim 1 wherein; R_s is 3-[4-(3-methoxyphenyl)piperazin-1-yl]propyl or 3-[4-(2-pyrimidinyl)piperazin-1-yl]propyl, and R_t is hydrogen or a salt thereof or a solvate thereof.
- 12. (Previously presented) A compound according to claim 1 wherein; R_s is 3-pyridyl or 3-(6-methoxy)pyridyl, and R_t is hydrogen or a salt thereof or a solvate thereof.
- 13. (Previously presented) A compound according to claim 1 wherein;

 R_s is 2,2,6,6-tetramethylpiperidin-4-yl, R_t is hydrogen, R3 is 3-ethoxy, and R₁ is 5-chloro or 5-methoxy or a salt thereof or a solvate thereof.
- 14. (Previously presented) A compound according to claim 1 wherein;

 R_s is 2,2,6,6- tetramethylpiperidin-4-yl, R_t is hydrogen, R_3 is 2-methoxy, 3-methoxy, 3-ethoxy, 3-propoxy, 3-benzyloxy, 3-(2-carboxyethoxy), 3-(2-hydroxyethoxy), 3-(2,3-dihydroxypropoxy), 3-(2-dimethylaminoethoxy) or 3-(3-aminopropoxy) and 3-hydroxy and R_4 is 5-methoxy or hydrogen or a salt thereof or a solvate thereof.

- · 15. (Previously presented) A compound according to claim 1 wherein;

 R_s is 1,2,2,6,6- pentamethylpiperidin-4-yl, R_t is hydrogen, and R₃ is 2-methoxy or 3
 ethoxy, and R₄ is 5-methoxy or hydrogen or a salt thereof or a solvate thereof.
 - 16. (Previously presented) A compound according to claim 1 wherein;
 R_s is 1-benzylpiperidin-4-yl, 1-(4-ethoxycarbonyl)butylpiperydin-4-yl, 1-(4-hydroxycarbonyl)butylpiperydin-4-yl and R_t is hydrogen or a salt thereof or a solvate thereof.
 - (Original) A compound selected from the list consisting of: 17. 4-(5,6-dichloro-1H-indol-2-yl)-3-ethoxy-N-(2,2,6,6-tetramethylpiperidin-4-yl)-benzamide; 4-(5,6-dichloro-1H-indol-2-yl)-3-benzyloxy-N-(2,2,6,6-tetramethylpiperidin-4-yl)-benzamide; 4-(5.6-dichloro-1H-indol-2-yl)-3-hydroxy-N-(2,2,6,6-tetramethylpiperidin-4-yl)-benzamide; 4-(5.6-dichloro-1H-indol-2-vl)-3-propoxy-N-(2,2,6,6-tetramethylpiperidin-4-yl)benzamide; 4-(5,6-dichloro-1H-indol-2-yl)-N-[3-[4-(3-methoxyphenyl)piperazin-1-yl]propyl]-3methoxybenzamide; 4-(5,6-dichloro-1H-indol-2-yl)-N-[3- [4- (2-pyrimidyl)piperazin-1-yl]propyl]-3methoxybenzamide; 4-(5,6-dichloro-1H-indol-2-yl)-N-(2,2,6,6-tetramethylpiperidin-4-yl)-3-methoxybenzamide; 4-(5,6-dichloro-1H-indol-2-yl)-N-(1,2,2,6,6-pentamethylpiperidin-4-yl)-3-ethoxybenzamide; 4-(5,6-dichloro-1H-indol-2-yl)-N-(3-pyridyl)-3-ethoxybenzamide; 4-(5,6-dichloro-1H-indol-2-yl)-N-(3-(6-methoxypyridyl))-3-ethoxybenzamide; 4-(5,6-dichloro-1H-indol-2-yl)-N-(1-benzylpiperidin-4-yl)-3-ethoxybenzamide; 4-(5,6-dichloro-1H-indol-2-yl)-N-(2,2,6,6-tetramethylpiperidin-4-yl)-2,5-dimethoxybenzamide; 4-(5,6-dichloro-1H-indol-2-yl)-N-(1,2,2,6,6-pentamethylpiperidin-4-yl)-2,5dimethoxybenzamide;

4-(5-methoxy-6-chloro-1H-indol-2-yl)-N-(2,2,6,6-tetramethylpiperidin-4-yl)-3-ethoxybenzamide; 4-(5,6-dichloro-1H-indol-2-yl)-3-methoxy-N-((1-ethoxycarbonylpentyl)piperidin-4-yl)-benzamide;

4-(5,6-dichloro-1H-indol-2-yl)-3-methoxy-N-((carboxybutyl)piperidin-4-yl)benzamide;

4-(5,6-dichloro-1H-indol-2-yl)-N-(2,2,6,6-tetramethylpiperidin-4-yl)-3-

(hydroxycarbonylmethoxy)benzamide;

4-(5,6-dichloro-1H-indol-2-yl)-N-(2,2,6,6-tetramethylpiperidin-4-yl)-3-(2-hydroxyethoxy)benzamide;

4-(5,6-dichloro-1H-indol-2-yl)-N-(2,2,6,6-tetramethylpiperidin-4-yl)-3-(3-amino-propoxy)benzamide;

4-(5,6-dichloro-1H-indol-2-yl)-N-(2,2,6,6-tetramethylpiperidin-4-yl)-3-(2-dimethylamino-ethoxy)benzamide, and;

4-(5,6-dichloro-1H-indol-2-yl)-N-(2,2,6,6-tetramethylpiperidin-4-yl)-3-(2,3-hydroxy-propoxy)benzamide.

18. (Original) A process for the preparation of a compound of formula (I) as defined in claim 1 or a salt thereof or a solvate thereof, which process comprises the amidation of a compound of formula (II)

$$R_1$$
 R_2
 R_3
 R_4
 OH
 OH
 OH

wherein;

 $R_{1'}$, $R_{2'}$, $R_{3'}$, and $R_{4'}$ each respectively represent R_1 , R_2 , R_3 , and R_4 as defined in relation to formula (I) or a protected from thereof, with a compound of formula (III)

$HNR_{s'}R_{t'}$ (III)

wherein;

 $R_{s'}$ and $R_{t'}$ each represent R_{s} and R_{t} as defined in relation to formula (I) or a protected from thereof and thereafter, as necessary, carrying out one or more of the following steps:

- (i) converting one compound of formula (I) into another compound of formula (I);
- (ii) removing any protecting group;
- (iii) preparing a salt or solvate of the compound so formed.
- 19. (Original) A method for the treatment and/or prophylaxis of diseases associated with over activity of osteoclasts in mammals which method comprises the administration of an effective non-toxic amount of a compound of formula (I) as defined in claim 1, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof.
- 20. (Original) A method for the treatment of osteoporosis and related osteopenic diseases in a human or non-human mammal, which comprises administering an effective, non-toxic, amount of a compound of formula (I) as defined in claim 1 or a pharmaceutically acceptable salt thereof or a pharmaceutically acceptable solvate thereof, to a human or non-human mammal in need thereof.
- 21. (Currently amended) A method for the treatment of tumours, ulcers, autoimmune diseases, hypercholesterolemic and atherosclerotic diseases, AIDS, and angiogenic diseases, in a human or non-human mammal, which comprises administering an effective, non-toxic, amount of a compound of formula I according to claim 1 or a pharmaceutically acceptable salt thereof or a pharmaceutically acceptable solvate thereof, to a human or non-human mammal in need thereof.

22-25. (Canceled)

(Original) A pharmaceutical composition comprising a compound of formula as defined 26. in claim 1 or a pharmaceutically acceptable salt thereof or a pharmaceutically acceptable solvate thereof and a pharmaceutically acceptable carrier therefor.

27-29. (Canceled)